A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Duragesic (Fentanyl Transdermal System [TDS] Small Patches)Drug: Duragesic (Fentanyl TDS Large Patches)Drug: New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)Drug: New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)Drug: Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)Drug: Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 52
- Registration Number
- NCT02608320
A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT02606084
A Study to Investigate the Effect of JNJ-63623872 on Pitavastatin in Healthy Participants
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 14
- Registration Number
- NCT02595268
Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer
Phase 1
Terminated
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Biological: JNJ-64041757 (Cohort 1A and 1B)Biological: JNJ-64041757 (Cohort 2A and 2B)
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2018-11-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT02592967
A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT02570373
An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia
Phase 2
Terminated
- Conditions
- Asymptomatic Amyloid-positive
- Interventions
- Drug: PlaceboDrug: Atabecestat, 5 mgDrug: Atabecestat, 25 mg
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 557
- Registration Number
- NCT02569398
Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 71
- Registration Number
- NCT02568176
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 841
- Registration Number
- NCT02555878
A Registry of Participants With Prostate Cancer in Asia
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- Other: No Intervention
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 3644
- Registration Number
- NCT02546908
A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 848
- Registration Number
- NCT02546960
© Copyright 2025. All Rights Reserved by MedPath